CAZypedia needs your help! We have many unassigned GH, PL, CE, AA, GT, and CBM pages in need of Authors and Responsible Curators.
Scientists at all career stages, including students, are welcome to contribute to CAZypedia. Read more here, and in the 10th anniversary article in Glycobiology.
New to the CAZy classification? Read this first.
*
Consider attending the 15th Carbohydrate Bioengineering Meeting in Ghent, 5-8 May 2024.

Difference between revisions of "User:Kyle Robinson"

From CAZypedia
Jump to navigation Jump to search
(fixed intra-wiki links, replaced photo placeholder)
Line 1: Line 1:
[[Image:Blank_user-200px.png|200px|right]]
+
[[Image:Profile.jpg|200px|right]]
 
Kyle Robinson began his studies at [https://en.wikipedia.org/wiki/McGill_University McGill University], where he completed his B.Sc. while studying under Prof. Paul Wiseman. He has since been pursuing his PhD at the University of British Columbia under the supervision of Prof. [[User:Steve_Withers|Stephen Withers]]. His research focuses on the design of selective mechanism-based inhibitors for glycosyl hydrolases, specifically, sialidases and trans-sialidases from [[Glycoside Hydrolase Family 33]].
 
Kyle Robinson began his studies at [https://en.wikipedia.org/wiki/McGill_University McGill University], where he completed his B.Sc. while studying under Prof. Paul Wiseman. He has since been pursuing his PhD at the University of British Columbia under the supervision of Prof. [[User:Steve_Withers|Stephen Withers]]. His research focuses on the design of selective mechanism-based inhibitors for glycosyl hydrolases, specifically, sialidases and trans-sialidases from [[Glycoside Hydrolase Family 33]].
  

Revision as of 20:31, 10 August 2015

Profile.jpg

Kyle Robinson began his studies at McGill University, where he completed his B.Sc. while studying under Prof. Paul Wiseman. He has since been pursuing his PhD at the University of British Columbia under the supervision of Prof. Stephen Withers. His research focuses on the design of selective mechanism-based inhibitors for glycosyl hydrolases, specifically, sialidases and trans-sialidases from Glycoside Hydrolase Family 33.